Bacampicillin is a new oral prodrug which is rapidly converted to ampicillin during absorption from the gastrointestinal tract. High serum peaks of ampicillin are obtained. Bacampicillin orally was compared pharmacokinetically with parenteral ampicillin (intravenously and intramuscularly). A cross-over study on healthy volunteers showed that ampicillin concentrations after equimolar doses of bacampicillin orally and ampicilhin intramuscularly were of the same order. The mean of the individual peak values (regardless of time of occurrence) after a dose of 800 mg of bacampicillin was 13.1 ± 3.8 ,tg/ml. Absorption rates of the two doses were similar, as were their distribution volumes (approximately 25% of the body weight). Bioavailability was 87% for bacampicillin, compared to 71% for ampicillin.
Bacampicillin is a new oral prodrug which is rapidly converted to ampicillin during absorption from the gastrointestinal tract. High serum peaks of ampicillin are obtained. Bacampicillin orally was compared pharmacokinetically with parenteral ampicillin (intravenously and intramuscularly). A cross-over study on healthy volunteers showed that ampicillin concentrations after equimolar doses of bacampicillin orally and ampicilhin intramuscularly were of the same order. The mean of the individual peak values (regardless of time of occurrence) after a dose of 800 mg of bacampicillin was 13.1 ± 3.8 ,tg/ml. Absorption rates of the two doses were similar, as were their distribution volumes (approximately 25% of the body weight). Bioavailability was 87% for bacampicillin, compared to 71% for ampicillin.
Bacampicillin (code number A 2393) is a new semisynthetic ester of ampicillin, chemically l'-[(ethoxycarbonyl)oxy]ethyl-6-(D-a-aminophenylacetamido) penicillinate-hydrochloride, with a pK. of 6.8 at 250C. The substitution at the ampicillin thiazolidine carboxy group makes bacampicillin less polar (higher lipid solubility at physiological pH) without appreciably changing the water solubility; therefore it has a better bioavailability than ampicillin upon oral intake (2, 20, 26a) .
Upon absorption, bacampicillin is rapidly hydrolyzed to ampicillin (2; A. Swahn, Ph.D. thesis, Karolinska Institute, Stockholm, Sweden, 1974), which is the antibacterial principle.
In this report, the pharmacokinetic characteristics of oral bacampicillin will be compared with those of ampicillin injected intravenously and intramuscularly.
MATERIALS AND METHODS
Plan of study. After fasting at least from midnight, the subjects received either 800 mg of bacampicillin (batch F81) orally (2 tablets) Bioavailability. The bioavailability of the two extravascular dosage forms was assessed on the basis of the Dost theorem of equivalence of corresponding areas under curves of serum concentration versus time (F) following equal doses of the same drug (7). The i.v. dose is used as the 100% reference point.
The area under the serum curve till infinity after the i.v. dose was 40.3 ± 7.19 ytg/h per ml.
Bacampicillin had a mean bioavailability of 87 ± 21.8% and ampicillin i.m. was 71.0 ± 21.4%. The ratio of the areas under the curves, Fbacam.
picillin to FampiciRin i.m., was 1.2.
DISCUSSION
Bacampicillin is a prodrug which is rapidly and completely hydrolyzed to render plain ampicillin during or immediately after absorption. Even with the most sensitive technique, bacampicillin has never been found in serum of humans or animals (2; A. Swahn, Ph.D. thesis). Thus, nonspecific artifacts derivable from degradation in vitro following blood sampling are not applicable to bacampicillin as with, e.g., hetacillin (14) . The blood samples do not contain largely inactive bacampicillin which liberates ampicillin only after sampling. Thus, both pharmacokinetic evaluations and bioavailability estimates are validly based on ampicillin.
The serum concentrations observed after bacampicillin and ampicillin i.m. or i.v. were of the same order as implemented by similar doses in other investigations (3, 5, 11, 13-15, 18, 20-22, 26-27) . It is important to note that the mean values obtained here are completely superimposable on the curves of Simon (26) after the same doses of bacampicillin orally and ampicillin i.v. After 1 h, the serum levels after oral bacampicillin were above those obtained by both equimolar parenteral doses of ampicillin. After 6 h, serum concentrations after bacampicillin were twice those observed after the other doses. The serum concentrations after bacampicillin were two to four times higher than after comparable doses of ampicillin orally, when only 2-4 ,lg/ml would be expected (12, 16, 17, 21, 26, 26a) .
A concentration of 5 jig of ampicillin per ml is often considered an upper level of susceptibility, since 70 to 80% of Escherichia coli require for inhibition minimum inhibitory concentrations below this level (9, 23) . Except for rare betalactamase-producing strains, Haemophilus influenzae requires miniimum inhibitory concentrations of ampicillin below 1.0 ,tg/ml (30) . The i.m. doses used in these experiments would render serum levels of ampicillin above 5 ,tg/ml for about 2 h, of bacampicillin for some 3 h.
The presently calculated pharmacokinetic parameters were of the same order as found by others (3) (4) (5) , although differing values have also been reported for similar doses (19) . 4), but higher than the 17.9 liters observed by Jusko and Lewis (14) . The bioavailability of bacampicillin (87%) and that of ampicillin i.m. (71%) are both above the 40 to 55% noted for ampicillin tablets or capsules (3). Similar i.m. bioavailability has been found by others (8, 23) , although up to 90% has been found (25) .
It would appear that bacampicillin is favorable in terms of absorption rate and percentage absorbed. The ampicillin levels rendered by bacampicillin are above those after equimolar sodium ampicillin i.m. or i.v. for substantial portions of a normal dosage interval.
